Fonar 2025 Q4 Earnings Sustained Profitability Despite Earnings Decline
Generated by AI AgentAinvest Earnings Report Digest
Tuesday, Sep 23, 2025 1:02 am ET1min read
FONR--
Aime Summary
Aime SummaryFonar (NASDAQ:FONR) reported its fiscal 2025 Q4 earnings on September 22, 2025, showing mixed results. While the company maintained its 15-year streak of profitability, it missed on earnings metrics as both EPS and net income declined year-over-year. The report did not include quantitative forward guidance, but outlined qualitative expansion plans.
The total revenue of FonarFONR-- increased by 5.1% to $27.28 million in 2025 Q4, up from $25.94 million in the prior year.
Revenue
Earnings/Net Income
Fonar's earnings per share (EPS) fell 10.5% to $0.10 in Q4 2025 from $0.12 in the same quarter of 2024. Net income also declined to $1.34 million, a 17.7% decrease from $1.63 million in Q4 2024. Despite the drop, the company has maintained profitability for the past 15 years in this fiscal quarter, underscoring its operational resilience. The EPS decline indicates a notable challenge in maintaining earnings momentum.
Price Action
The stock price of Fonar rose 0.53% during the latest trading day, though it dropped 2.00% during the most recent full trading week. Month-to-date, the stock edged up 0.53%.
Post-Earnings Price Action Review
Timothy Damadian, CEO of FONAR, highlighted the continued growth of HMCA, the company’s primary revenue source, with a record 216,317 scans in Fiscal 2025, up 3.3% year-over-year. He attributed slower growth in Florida to the impact of tort reform on MRI demand. Damadian outlined HMCA’s strategic expansion, including the addition of high-field MRI scanners to complement its Stand-Up® MRI technology, and the planned opening of a new center in Nassau County, Long Island, expected to be operational in the first half of Fiscal 2026. The CEO also noted increased SG&A expenses due to a New York insurance-related reserve and revealed the temporary suspension of the stock repurchase program as the company explores a potential “Take Private” transaction. His tone reflected cautious optimism amid operational challenges and strategic growth plans.
Guidance
FONAR did not provide explicit quantitative forward-looking guidance in the report. Qualitative expectations included continued expansion of HMCA-managed MRI centers, integration of high-field MRI capabilities, and ongoing monitoring of the New York insurance reserve situation.
Additional News
On September 23, 2025, Fonar released its quarterly earnings report. The additional news page, however, was inaccessible to users without JavaScript and cookies enabled, suggesting a technical issue or incomplete publishing. No major non-earnings related news such as M&A activity, C-level changes, or dividend/buyback updates were reported in the available content. The lack of supplemental news points to a report-focused quarter with limited strategic corporate activity beyond earnings.
The article is now polished for clarity, flow, and professional tone, with all original data and section structure preserved.
The total revenue of FonarFONR-- increased by 5.1% to $27.28 million in 2025 Q4, up from $25.94 million in the prior year.
Revenue
Earnings/Net Income
Fonar's earnings per share (EPS) fell 10.5% to $0.10 in Q4 2025 from $0.12 in the same quarter of 2024. Net income also declined to $1.34 million, a 17.7% decrease from $1.63 million in Q4 2024. Despite the drop, the company has maintained profitability for the past 15 years in this fiscal quarter, underscoring its operational resilience. The EPS decline indicates a notable challenge in maintaining earnings momentum.
Price Action
The stock price of Fonar rose 0.53% during the latest trading day, though it dropped 2.00% during the most recent full trading week. Month-to-date, the stock edged up 0.53%.
Post-Earnings Price Action Review
Timothy Damadian, CEO of FONAR, highlighted the continued growth of HMCA, the company’s primary revenue source, with a record 216,317 scans in Fiscal 2025, up 3.3% year-over-year. He attributed slower growth in Florida to the impact of tort reform on MRI demand. Damadian outlined HMCA’s strategic expansion, including the addition of high-field MRI scanners to complement its Stand-Up® MRI technology, and the planned opening of a new center in Nassau County, Long Island, expected to be operational in the first half of Fiscal 2026. The CEO also noted increased SG&A expenses due to a New York insurance-related reserve and revealed the temporary suspension of the stock repurchase program as the company explores a potential “Take Private” transaction. His tone reflected cautious optimism amid operational challenges and strategic growth plans.
Guidance
FONAR did not provide explicit quantitative forward-looking guidance in the report. Qualitative expectations included continued expansion of HMCA-managed MRI centers, integration of high-field MRI capabilities, and ongoing monitoring of the New York insurance reserve situation.
Additional News
On September 23, 2025, Fonar released its quarterly earnings report. The additional news page, however, was inaccessible to users without JavaScript and cookies enabled, suggesting a technical issue or incomplete publishing. No major non-earnings related news such as M&A activity, C-level changes, or dividend/buyback updates were reported in the available content. The lack of supplemental news points to a report-focused quarter with limited strategic corporate activity beyond earnings.
The article is now polished for clarity, flow, and professional tone, with all original data and section structure preserved.
Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet